Abstracts

In Vivo Detection of HIV-1 Antisense Transcripts in Donors Before and During ART

Background: Natural antisense transcripts (NATs) are expressed by viruses, prokaryotes, and eukaryotes and primarily function in regulating sense gene expression through multiple mechanisms. In vivo studies have shown that HIV-1 expresses antisense transcripts (AST) from a Tat-independent negative sense promoter in the 3′ LTR. In cell line studies, AST was demonstrated to promote HIV latency…

A Capillary Blood-Based Self-Collection Method for Monitoring HIV Viral Load During ART Interruption

Background: Multiple barriers limit participation of people with HIV (PWH) in studies in which frequent viral load (VL) monitoring is required such as cure studies involving a treatment interruption (ATI). Convenient, home-based VL testing may increase equitable participation. Here we report a novel VL test based on capillary blood collection, comparing its specificity and sensitivity…

HIV-1 Outbreak Among PWID in Thessaloniki: Recent Expansion in the Midst of COVID-19 Pandemic

Background: During the implementation of ‘ALEXANDROS’, a community-based programme, an HIV-1 outbreak was identified among people who inject drugs (PWID) in Thessaloniki, the second largest city in Greece, between 2019 and 2021. Preliminary phylogenetic analysis suggested that 25 sequences from PWID sampled in Thessaloniki during 2019-2021, belonged to 3 phylogenetic clusters of subsubtype A6 and…

Risk of SARS-CoV-2 Infection in Patients With Hematologic Diseases Receiving Tixagevimab/Cilgavimab

Background: Despite in vitro data showing poor neutralizing activity, clinical efficacy of tixagevimab/cilgavimab (T/C) as pre-exposure prophylaxis (PrEP) in patients (pts) with hematological disease (HD) against the newest omicron sub-variants of SARS-CoV-2 was rarely investigated and long-term incidence data are lacking Methods: Observational study of pts with HD who received 300 mg of T/C given…

Factors Associated With HBV Response to B/F/TAF vs DTG + F/TDF at W96 in People With HIV-1 and HBV

Background: The Phase 3 ALLIANCE study investigated the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs. dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in people initiating therapy for HIV-1 and HBV. Over 96 weeks (W), B/F/TAF showed significantly higher rates of HBeAg loss/seroconversion, and numerically higher rates of HBsAg loss/seroconversion and ALT normalization, vs. DTG+F/TDF. Overall,…

Non-Invasive Imaging Identifies Elevated Metabolic Activity in Lymphoid Tissue During Long-Term ART

Background: Mechanisms of HIV persistence in anatomic compartments remain poorly understood. Positron Emission Tomography (PET) is a non-invasive technique that may provide insights to the spatial distribution and microenvironment of HIV persistence and identify sites for tissue sampling. Early 18F-fluorodeoxyglucose PET (FDG-PET) techniques did not detect elevated metabolic activity during long-term antiretroviral therapy (ART), though…

Intact Proviruses Persist in Expressed Genes in People With Non-Suppressible HIV on Long-Term ART

Background: The persistence of replication-competent proviruses during ART is a key barrier to an HIV cure. A previous study identified 3 cell clones carrying replication-competent proviruses that were integrated in genes and were the sources of non-suppressible viremia (NSV). Here, we asked if additional clones carrying intact proviruses were present in these 3 individuals; and,…